Manufacturing vs. Clinical Sites: The Missing Investment in Radiopharma Development
.png)
Manufacturing vs. Clinical Sites: The Missing Investment in Radiopharma Development
Radiopharmaceutical development is scaling quickly. Manufacturing capacity is expanding. Isotope supply is becoming more reliable. Investment is accelerating across the industry.
At first glance, this looks like a system preparing for growth.
But one part of the system is not keeping pace: clinical trial sites.
While manufacturing scales, clinical infrastructure remains limited. This imbalance is becoming a defining constraint in radiopharmaceutical development.
Manufacturing Is Scaling by Design
Manufacturing investment is a logical starting point. Radiopharmaceuticals depend on short lived isotopes, precise production, and tightly controlled delivery. These characteristics make reliability and scale essential.
Companies are investing heavily in production facilities and supply chains to support both current therapies and future pipelines. This includes therapies such as lutetium-177 based treatments, which are already used in prostate cancer and neuroendocrine tumors.
This aligns with broader scientific progress. Radiopharmaceuticals are expanding across both imaging and targeted therapy, with increasing clinical applications across oncology and other diseases [1].
Without manufacturing, there is no product.
But manufacturing alone does not move therapies through development.
Clinical Sites Are Not Scaling the Same Way
Clinical trial sites operate under a different set of constraints.
Radiopharmaceutical trials require coordination across nuclear medicine, imaging, oncology, radiation safety, radiopharmacy, and clinical research teams. They must support workflows tied to radioactive decay, imaging schedules, and patient specific dosing.
These requirements limit how many sites can participate.
Unlike manufacturing facilities, clinical sites are typically part of health systems. They must balance research with routine patient care and depend on trained specialists who are already in limited supply.
Health system analyses show that delivering radioligand therapy requires coordinated infrastructure, trained teams, referral pathways, and regulatory alignment [2].
This is not easily scalable.
The Result Is a Growing Imbalance
This creates a structural disconnect.
Manufacturing capacity is being built for future demand. Clinical site capacity is being stretched to support current trials.
In practical terms, the system is preparing to produce more therapies than it can efficiently test.
Recent literature describes radiopharmaceutical therapy as a rapidly growing field that depends on specialized expertise and coordinated clinical delivery [3].
That means the bottleneck is not only whether a therapy can be produced. It is whether the clinical system can support it.
Clinical Execution Determines Value
Radiopharmaceutical therapies generate value through clinical progress.
That progress depends on sites that can activate efficiently, teams that can execute complex protocols, infrastructure that supports imaging and dosing, and workflows that allow consistent patient throughput.
Global reviews highlight strong momentum in radioligand therapy, but also emphasize that access depends on infrastructure, workforce, regulatory alignment, and delivery capacity [4].
If site capacity is limited, development slows.
Even well-funded programs can face delays when clinical infrastructure is constrained. Timelines extend. Costs increase. The connection between investment and outcomes becomes less efficient.
Site Expansion Is Not Simple
Expanding clinical trial capacity is complex.
Implementation studies describe key barriers, including workforce gaps, training needs, regulatory variation, supply coordination, and uneven infrastructure [5].
Recent conference discussions also highlight differences in imaging and therapy capacity across regions, which affect how many patients can be treated and enrolled in trials [6].
These are system level challenges.
Clinical capacity cannot be built through capital alone.
Regulatory and Operational Complexity Reinforce the Gap
Radiopharmaceutical trials are becoming more complex.
Regulators are placing greater emphasis on dosing, safety, and imaging based endpoints. These requirements reflect the unique characteristics of radioactive therapies.
At the same time, operational demands remain high. Sites must manage radioactive materials, coordinate time sensitive procedures, and align multiple teams.
This increases the burden on clinical sites and raises the threshold for what qualifies as trial ready.
Theragnostic Insight - Manufacturing capacity can be scaled with capital. Clinical trial capacity depends on infrastructure, coordination, and expertise. Without investment in sites, development timelines will continue to be constrained.
What This Means for Sponsors and Investors
For sponsors, manufacturing readiness is not the same as development readiness.
Site strategy should be addressed early. That includes evaluating real capacity, understanding operational constraints, and supporting sites beyond basic activation.
For investors, manufacturing expansion is only part of the equation.
Key questions include:
Can clinical sites support the pace of development?
How dependent is the program on a limited number of centers?
What risks exist in activation and execution?
Where are the bottlenecks that could delay progress?
Without clear answers, timelines may be overestimated.
What This Means for You
Radiopharmaceutical development is often evaluated through the lens of manufacturing scale and pipeline strength.
But development timelines are ultimately determined by clinical execution.
When site capacity is limited, progress slows regardless of how advanced the science or how strong the supply chain may be. This creates a disconnect between investment and outcomes that is not always visible early in development.
At Theragnostic Insights, we focus on where that disconnect occurs. That includes evaluating how trial design, site capabilities, and operational realities align in practice.
Because in radiopharmaceutical development, success depends on how effectively therapies move through the clinic, not just how efficiently they can be produced.
Stay tuned for more in this mini-series: Clinical Capacity Crisis: The Hidden Bottleneck in Radiopharma Development.
In the coming weeks, we’ll continue exploring the clinical capacity crisis holding back radiopharmaceutical innovation, from regional access gaps to operational gridlock and infrastructure blind spots. Don’t miss the next post as we map out the road to a truly trial-capable ecosystem.
- The Trial Site Gap: Why Radiopharmaceutical Innovation Is Hitting a Wall
- Geography Is Destiny: The Clinical Access Gaps in Radiopharmaceutical Research
- Operational Gridlock: Where Radiopharmaceutical Trials Break Down on Site
- Beyond the Badge: Rethinking What “Trial-Ready” Really Means in Radiopharma
- Infrastructure as Investment Strategy: Clinical Site Access and Radiopharma ROI
- Built for What’s Next: Redefining Clinical Site Design for Theragnostic Trials
- Speed as Strategy: How Site Scarcity Is Slowing Radiopharmaceutical Pipelines
- One Roof, Many Bottlenecks: Why Fragmented Site Models Undermine RLT Trials
- The Dosimetry Dilemma: Why Many Sites Aren’t Ready for Radioligand Trials
- Licensing & Radiation Safety: The Regulatory Maze Behind Radiopharmaceutical Trials
- The Hidden Role of Radiation Safety in Clinical Trial Activation
- The Radiopharma Workforce Gap: Who’s Actually Running These Trials?
- The Infrastructure Nobody Funds: Why Clinical Trial Sites Are Missing From Radiopharma Investment
- Manufacturing vs. Clinical Sites: The Missing Investment in Radiopharma Development
References:
[1] Zhang et al., 2025. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy
[2] Health Policy Partnership, 2024. Health system readiness for radioligand therapy in the US: Service provision. Health System Readiness
[3] Jacene et al., 2025. Radiopharmaceutical Therapy: Rapid Growth, Rising Challenges, and the Critical Need for Expertise. Journal of Nuclear Medicine
[4] Cancers, 2025. Radioligand Therapy in Cancer Management: A Global Perspective. MDPI
[5] International Atomic Energy Agency authors, 2025. Implementation of Radiotheranostics: Challenges, Barriers, and IAEA Recommendations. Seminars in Nuclear Medicine
[6] UroToday, 2025. ESMO 2025: Scaling up Capacity to Deliver Radioligand Therapeutics. UroToday
https://www.nature.com/articles/s41392-024-02041-6
https://jnm.snmjournals.org/content/early/2025/10/23/jnumed.125.271028
https://www.mdpi.com/2072-6694/17/21/3412
https://www.sciencedirect.com/science/article/pii/S0001299825001102
